Navigation Links
Montclair Breast Center introduces 3D Mammography.
Date:5/2/2013

Montclair, NJ (PRWEB) May 02, 2013

Montclair Breast Center is one of the first women’s centers in New Jersey to offer 3D mammography (breast tomosynthesis) for breast cancer screening. Breast tomosynthesis produces a three-dimensional view of the breast tissue that helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue.

The center’s Selenia® Dimensions® breast tomosynthesis system is made by Hologic, a world leader in digital mammography. The Selenia Dimensions system offers exceptionally sharp breast images, an advanced ergonomic design providing more patient comfort, and the ground-breaking tomosynthesis platform designed to deliver superior screening and diagnostic performance.

Breast tomosynthesis will benefit all screening and diagnostic mammography patients, and is especially valuable for women receiving a baseline screening, those who have dense breast tissue and/or women with a personal history of breast cancer.

Breast cancer screening with tomosynthesis when combined with a conventional 2D mammography has a higher cancer detection rate than conventional 2D mammography alone.{1} Tomosynthesis technology gives radiologists increased confidence with a significant reduction in recall rates. {2}

The tomosynthesis screening experience is similar to a traditional mammogram. During a tomosynthesis exam, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a 3D reconstruction of the breast.

Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent. {3}

Of patients who began and continued their screening at Montclair Breast Center and were diagnosed with breast cancer in 2012, 95% were diagnosed at the most treatable Stages 0 or 1. The national average for such early diagnosis in all women is just 60%. This extremely high rate of early detection reflects Montclair Breast Center’s breast imaging expertise, physician/patient collaboration, and attention to detail.

In offering breast tomosynthesis digital mammography, Montclair Breast Center provides the latest in imaging technology. If you would like to schedule a 3D mammogram or have questions about this important breast health procedure, please visit Montclair Breast Center, or call 973-509-1818.

About Montclair Breast Center: Montclair Breast Center is a premier, multidisciplinary breast center, specializing in proactive breast healthcare, risk-reduction techniques and the early detection and treatment of breast cancer. Our nationally recognized, dedicated team of breast imagers and breast surgeons use the most sophisticated technologies and are committed to providing better breast care than anywhere.

{1} Skaane P, Gullien R, Eben EB, et. al. Reading time of FFDM and tomosynthesis in a population-based screening program. Radiological Society of North America annual meeting. Chicago, Il, 2011.
{2} Hologic, Inc. FDA PMA submission P080003.
{3} Breast Cancer Facts & Figures 2011, American Cancer Society.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10689120.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stereotactic Breast Biopsy introduced with Fischer-Giotto Image at American Society of Breast Surgeons course
2. Robert Lowen MD, Expert Bay Area Plastic Surgeon, Announces Cutting-Edge 3-D Crisalix Imaging Technology to Aid Patients in Choosing their Breast Implant Size
3. Patti Flint MD, A Top Female Plastic Surgeon in the Southwest, Is Proud To Offer Cutting-Edge 3D Crisalix Technology to Patients When Selecting Breast Implants
4. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
5. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
6. The First Dedicated Breast Cancer Cell Line Transfection Reagent
7. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
8. University of Maryland Breast Cancer Research Pioneer Dr. Angela Brodie Appointed Fellow of New American Association for Cancer Research Academy
9. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
10. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
11. Frost & Sullivan: Modest Growth Projected in the U.S. Breast Imaging Systems Market Amidst Increasing Breast Cancer Prevalence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):